Table 3.

Treatment-emergent ocular adverse events with onset during the 2-month study extension in patients treated with DEX at month 6 (safety population)^a

Adverse event, n (%)	Initial DEX treatment and month 6 DEX re-treatment (n = 107)	Initial sham treatment and month 6 DEX treatment (n = 96)
IOP increased	25 (23.4)	22 (22.9)
Conjunctival hemorrhage	10 (9.3)	10 (10.4)
Conjunctival hyperemia	6 (5.6)	5 (5.2)
Ocular hypertension	3 (2.8)	0 (0)

DEX dexamethasone intravitreal implant, IOP intraocular pressure

^aAll treatment-emergent ocular adverse events with onset after month 6 that were reported in >2% of patients in either treatment group are listed